Clinical Trial

Longitudinal Study of the GLUcagon REsponse to Hypoglycemia in Children and Adolescents With New-onset Type 1 DIAbetes

Study acronym: GLUREDIA
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated January 13, 2025 (before its estimated October 25, 2025 completion). Its status may not reflect the trial's current state.
Summary
The GLUREDIA study investigates the counter-regulatory response (CRR) during hypoglycemia in children with type 1 diabetes (T1D). Hypoglycemia can lead to severe symptoms, but is normally counteracted by CRR, corresponding to the secretion of hormones to maintain normoglycemia. Hypoglycemia is common in T1DM but some patients develop severe hypoglycemia as a result of CRR dysfunction. Despite several studies in adults, the presence of CRR dysfunction remains unpredictable and not well understood. The objective of GLUREDIA is therefore to describe and predict the evolution of CRR in children with T1DM.
Trial Details
NCT Number NCT06770621
Lead Sponsor Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Collaborators: The Leona M. and Harry B. Helmsley Charitable Trust
Conditions Severe Hypoglycemia, Type1diabetes
Enrollment 1,000 participants
Start Date 2022-05-25
Primary Completion 2025-10-25 (estimated)
Study Completion 2025-10-25 (estimated)
Updated on ClinicalTrials.gov 2025-01-13